# Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

> **NCT07357051** · PHASE3 · RECRUITING · sponsor: **Joincare Pharmaceutical Group Industry Co., Ltd** · enrollment: 177 (estimated)

## Conditions studied

- Respiratory Viral Infection

## Interventions

- **DRUG:** JKN2301 Dry Suspension
- **DRUG:** Oseltamivir Placebo
- **DRUG:** Oseltamivir
- **DRUG:** JKN2301 Placebo

## Key facts

- **NCT ID:** NCT07357051
- **Lead sponsor:** Joincare Pharmaceutical Group Industry Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-04-15
- **Target enrollment:** 177 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07357051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07357051, "Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07357051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*